Welcome to LookChem.com Sign In|Join Free

CAS

  • or

54-21-7

Post Buying Request

54-21-7 Suppliers

Recommended suppliersmore

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

54-21-7 Usage

Description

Sodium salicylate is a sodium salt of salicylic acid. It can be prepared from sodium phenolate and carbon dioxide under higher temperature and pressure. Historically, it has been synthesized from methyl salicylate (found in wintergreen plants or the bark of sweet birch tree) by reacting it with an excess of sodium hydroxide and heating it under reflux.

Chemical Properties

Different sources of media describe the Chemical Properties of 54-21-7 differently. You can refer to the following data:
1. Sodium salicylate, HOC6H4COONa, is a shiny, white powder with sweetish taste and mild aromatic aroma that is soluble in water,glycerol, and alcohol.Used in medicine and as a preservative.
2. Sodium salicylate is of the salicylate family and this compound is known to trigger Reye's Syndrome in children and adults, usually following a viral infection such as influenza or chicken pox. Products containing such salicylates should not be given to children under the age of 19.

Uses

Different sources of media describe the Uses of 54-21-7 differently. You can refer to the following data:
1. In manufacture of aspirin, methyl salicylate, and other salicylates. Coupling agent for azo dyes. Has been used as food preservative.
2. It is used in medicine as an analgesic and antipyretic. Sodium salicylate also acts as non - steroidal anti - inflammatory drug (NSAID), and induces apoptosis in cancer cells and also necrosis. It is also a potential replacement for aspirin for people sensitive to it. It may also be used as a phosphor for the detection of vacuum ultra violet radiation and electrons.

Definition

A salt or ester of salicylic acid.

Brand name

Alysine (Marion Merrell Dow).

General Description

Sodium salicylate may be prepared by the reaction, in aqueoussolution, by adding equal molar ratio of salicylic acidand sodium bicarbonate; evaporating to dryness yields thewhite salt. In solution, particularly in the presence of sodiumbicarbonate, the salt will darken on standing. This is the saltof choice for salicylate medication and usually is administeredwith sodium bicarbonate to lessen gastric distress, or itis administered in enteric coated tablets. However, the useof sodium bicarbonate is ill advised, because it decreases theplasma levels of salicylate and increases the excretion offree salicylate in the urine.Sodium salicylate, even though not as potent as aspirinfor pain relief, also has less GI irritation and is useful for patientswho are hypersensitive to aspirin.

Biochem/physiol Actions

Cell permeable: yes

Safety Profile

Experimental poison by subcutaneous route. Moderately toxic to humans by ingestion. Moderately toxic experimentally by ingestion, intraperitoneal, and intravenous routes. An experimental teratogen. Human systemic effects by multiple and unspecified routes: toxic psychosis, excitement, respiratory stimulation, nausea or vomiting, and sweating. Experimental reproductive effects. Mutation data reported. A powerful irritant which affects the central nervous system. Incompatible with ferric salts, mineral acids, iodme, lead acetate, silver nitrate, sodium phosphate powder. When heated to decomposition it emits toxic fumes of Na2O.

Check Digit Verification of cas no

The CAS Registry Mumber 54-21-7 includes 5 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 2 digits, 5 and 4 respectively; the second part has 2 digits, 2 and 1 respectively.
Calculate Digit Verification of CAS Registry Number 54-21:
(4*5)+(3*4)+(2*2)+(1*1)=37
37 % 10 = 7
So 54-21-7 is a valid CAS Registry Number.
InChI:InChI=1/C7H6O3.Na/c8-6-4-2-1-3-5(6)7(9)10;/h1-4,8H,(H,9,10);/q;+1/p-1

54-21-7 Well-known Company Product Price

  • Brand
  • (Code)Product description
  • CAS number
  • Packaging
  • Price
  • Detail
  • Alfa Aesar

  • (A17056)  Sodium salicylate, 99%   

  • 54-21-7

  • 250g

  • 371.0CNY

  • Detail
  • Alfa Aesar

  • (A17056)  Sodium salicylate, 99%   

  • 54-21-7

  • 1000g

  • 1223.0CNY

  • Detail
  • Sigma-Aldrich

  • (31493)  Sodiumsalicylate  puriss. p.a., Reag. Ph. Eur., 99.5-101.0% (calc. to the dried substance)

  • 54-21-7

  • 31493-250G

  • 1,091.61CNY

  • Detail
  • Sigma-Aldrich

  • (31493)  Sodiumsalicylate  puriss. p.a., Reag. Ph. Eur., 99.5-101.0% (calc. to the dried substance)

  • 54-21-7

  • 31493-1KG

  • 3,199.95CNY

  • Detail
  • Sigma-Aldrich

  • (71945)  Sodiumsalicylate  puriss. p.a., ≥99.5% (NT)

  • 54-21-7

  • 71945-250G

  • 923.13CNY

  • Detail
  • Sigma-Aldrich

  • (71945)  Sodiumsalicylate  puriss. p.a., ≥99.5% (NT)

  • 54-21-7

  • 71945-1KG

  • 2,888.73CNY

  • Detail
  • Vetec

  • (V900125)  Sodiumsalicylate  Vetec reagent grade, 99%

  • 54-21-7

  • V900125-500G

  • 150.64CNY

  • Detail
  • Sigma-Aldrich

  • (S0800000)  Sodiumsalicylate  European Pharmacopoeia (EP) Reference Standard

  • 54-21-7

  • S0800000

  • 1,880.19CNY

  • Detail
  • USP

  • (1614636)  Sodiumsalicylate  United States Pharmacopeia (USP) Reference Standard

  • 54-21-7

  • 1614636-500MG

  • 4,470.57CNY

  • Detail

54-21-7SDS

SAFETY DATA SHEETS

According to Globally Harmonized System of Classification and Labelling of Chemicals (GHS) - Sixth revised edition

Version: 1.0

Creation Date: Aug 17, 2017

Revision Date: Aug 17, 2017

1.Identification

1.1 GHS Product identifier

Product name Sodium salicylate

1.2 Other means of identification

Product number -
Other names salisod

1.3 Recommended use of the chemical and restrictions on use

Identified uses For industry use only.
Uses advised against no data available

1.4 Supplier's details

1.5 Emergency phone number

Emergency phone number -
Service hours Monday to Friday, 9am-5pm (Standard time zone: UTC/GMT +8 hours).

More Details:54-21-7 SDS

54-21-7Synthetic route

carbon dioxide
124-38-9

carbon dioxide

sodium phenoxide
139-02-6

sodium phenoxide

A

sodium salicylate
54-21-7

sodium salicylate

B

sodium 4-hydroxybenzoate
114-63-6

sodium 4-hydroxybenzoate

Conditions
ConditionsYield
With Triethylene glycol dimethyl ether at 80℃; for 10h; Product distribution; var. polyethers;A 80%
B 20%
at 119.84℃; under 60006 Torr; for 1h; Product distribution; Further Variations:; Pressures; N2 content; Kolbe-Schmitt reaction;
sodium 2-methoxybenzoate
17264-78-7

sodium 2-methoxybenzoate

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With piperazine In N,N-dimethyl acetamide at 150℃; for 24h; Substitution; Demethylation;12%
bis(phenyl) carbonate
102-09-0

bis(phenyl) carbonate

sodium ethanolate
141-52-6

sodium ethanolate

A

sodium salicylate
54-21-7

sodium salicylate

B

Phenetole
103-73-1

Phenetole

Conditions
ConditionsYield
beim Destillieren;
ethyl phenyl carbonate
3878-46-4

ethyl phenyl carbonate

sodium phenoxide
139-02-6

sodium phenoxide

A

sodium salicylate
54-21-7

sodium salicylate

B

Phenetole
103-73-1

Phenetole

Conditions
ConditionsYield
at 200℃;
carbonic acid ethyl ester-(2-isopropyl-5-methyl-phenyl ester)

carbonic acid ethyl ester-(2-isopropyl-5-methyl-phenyl ester)

sodium phenoxide
139-02-6

sodium phenoxide

A

thymol
89-83-8

thymol

B

sodium salicylate
54-21-7

sodium salicylate

C

Phenetole
103-73-1

Phenetole

Conditions
ConditionsYield
at 200℃;
sodium benzoate
532-32-1

sodium benzoate

A

m-hydroxybenzoic acid sodium salt
7720-19-6

m-hydroxybenzoic acid sodium salt

B

sodium salicylate
54-21-7

sodium salicylate

C

sodium 4-hydroxybenzoate
114-63-6

sodium 4-hydroxybenzoate

Conditions
ConditionsYield
With phosphate buffer; Saline; 2-Deoxy-D-ribose; dinitrogen monoxide at 20 - 25℃; for 1h; Irradiation; var. OH scavengers;
C7H4(2)HO3(1-)*Na(1+)

C7H4(2)HO3(1-)*Na(1+)

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With water-d2 In water at 34.9℃; Equilibrium constant;
sodium benzoate
532-32-1

sodium benzoate

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With sulphapyridine; water Rate constant; Irradiation; also 5-, 4-, and 3-aminosalicylic acids;
salicylic acid
69-72-7

salicylic acid

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With KU-2(Na) Equilibrium constant; exchange equilibrium constant;
With sodium hydroxide In ethanol at 20℃;
bis(phenyl) carbonate
102-09-0

bis(phenyl) carbonate

sodium hydroxide

sodium hydroxide

A

sodium salicylate
54-21-7

sodium salicylate

B

phenol
108-95-2

phenol

Conditions
ConditionsYield
beim Destillieren;
bis(phenyl) carbonate
102-09-0

bis(phenyl) carbonate

sodium hydroxide

sodium hydroxide

A

carbon dioxide
124-38-9

carbon dioxide

B

sodium phenoxide
139-02-6

sodium phenoxide

C

sodium salicylate
54-21-7

sodium salicylate

D

phenol
108-95-2

phenol

Conditions
ConditionsYield
at 120 - 160℃; im Stickstoffstrom;
salicylic acid
69-72-7

salicylic acid

sodium bicarbonate

sodium bicarbonate

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With water Eindampfen nach Aufhoeren der CO2-Entwicklung im Wasserbade zur Trockne;
2-salicyloyloxy-benzoic acid methyl ester
85531-25-5

2-salicyloyloxy-benzoic acid methyl ester

aqueous-methanolic NaOH-solution

aqueous-methanolic NaOH-solution

A

sodium salicylate
54-21-7

sodium salicylate

B

methyl salicylate
119-36-8

methyl salicylate

Cu(2+)*OH(1-)*C6H4(OH)COO(1-)=Cu(OH)C7H5O3

Cu(2+)*OH(1-)*C6H4(OH)COO(1-)=Cu(OH)C7H5O3

A

sodium salicylate
54-21-7

sodium salicylate

B

copper hydroxide
20427-59-2

copper hydroxide

Conditions
ConditionsYield
With sodium hydroxide In not given equilibrium reaction;; not isolated; in soln.;;
With NaOH In not given equilibrium reaction;; not isolated; in soln.;;
C7H5O3(1-)*C56H98O35*Na(1+)
199009-79-5

C7H5O3(1-)*C56H98O35*Na(1+)

A

heptakis(2,6-di-O-methyl)cyclomaltoheptaose
51166-71-3

heptakis(2,6-di-O-methyl)cyclomaltoheptaose

B

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With pluronic copolymer F127 In water at 25℃; Equilibrium constant; Reagent/catalyst;
phenyl Salicylate
118-55-8

phenyl Salicylate

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With cetylpyridinium chloride; water; sodium hydroxide In ethanol at 41.84℃; Kinetics; Reagent/catalyst; Temperature;
phenol
108-95-2

phenol

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
Multi-step reaction with 2 steps
1: sodium hydroxide / water / 80 - 90 °C / Autoclave
2: sodium hydroxide / toluene / 1 h / 140 - 150 °C / 4500.45 - 6000.6 Torr
View Scheme
carbon dioxide
124-38-9

carbon dioxide

sodium phenoxide
139-02-6

sodium phenoxide

sodium salicylate
54-21-7

sodium salicylate

Conditions
ConditionsYield
With sodium hydroxide In toluene at 140 - 150℃; under 4500.45 - 6000.6 Torr; for 1h;
sodium salicylate
54-21-7

sodium salicylate

silver nitrate

silver nitrate

silver salicylate
528-93-8, 14800-64-7

silver salicylate

Conditions
ConditionsYield
In water for 1h;100%
In not given
In water by mixing a 0.1 M aq. soln. of sodium salicylate and an 0.1 M aq. soln.of AgNO3; the suspn. was centrifuged and the ppt. was washed with triply distd. water; dried at 60-90°C;
trihexyl(tetradecyl)phosphonium chloride
258864-54-9

trihexyl(tetradecyl)phosphonium chloride

sodium salicylate
54-21-7

sodium salicylate

trihexyl(tetradecyl)phosphonium salicylate
1228997-35-0

trihexyl(tetradecyl)phosphonium salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
In water; acetone at 20℃; for 24h; Inert atmosphere;95%
sodium salicylate
54-21-7

sodium salicylate

3-ethyl-1-methyl-1H-imidazol-3-ium bromide
65039-08-9

3-ethyl-1-methyl-1H-imidazol-3-ium bromide

1-ethyl-3-methylimidazolium 2-hydroxybenzoate
945611-28-9

1-ethyl-3-methylimidazolium 2-hydroxybenzoate

Conditions
ConditionsYield
In acetone for 72h;100%
In ethanol
sodium salicylate
54-21-7

sodium salicylate

1-butyl-3-methylimidazolium chloride
79917-90-1

1-butyl-3-methylimidazolium chloride

1-butyl-3-methyl-3H-imidazolium salicylate

1-butyl-3-methyl-3H-imidazolium salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
In acetonitrile at 20℃; for 24h; Inert atmosphere;95%
In acetone for 12h; Reflux;
In acetonitrile at 20℃;
sodium salicylate
54-21-7

sodium salicylate

1-dodecyl-3-methylimidazol-1-ium chloride

1-dodecyl-3-methylimidazol-1-ium chloride

1-dodecyl-3-methylimidazolium salicylate
1609103-02-7

1-dodecyl-3-methylimidazolium salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
1-ethyl-4-methylpyridin-1-ium bromide
32353-49-4

1-ethyl-4-methylpyridin-1-ium bromide

sodium salicylate
54-21-7

sodium salicylate

1-ethyl-4-methylpyridinium salicylate
1609103-03-8

1-ethyl-4-methylpyridinium salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
sodium salicylate
54-21-7

sodium salicylate

N-butyl-4-methylpyridinium bromide
65350-59-6

N-butyl-4-methylpyridinium bromide

1-butyl-4-methylpyridinium salicylate
1609103-04-9

1-butyl-4-methylpyridinium salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
choline chloride
67-48-1

choline chloride

sodium salicylate
54-21-7

sodium salicylate

choline salicylate
2016-36-6

choline salicylate

Conditions
ConditionsYield
In acetone for 72h;100%
In ethanol at 20℃; for 1h;
sodium salicylate
54-21-7

sodium salicylate

procaine hydrochloride
51-05-8

procaine hydrochloride

procainium salicylate
4344-99-4

procainium salicylate

Conditions
ConditionsYield
In water; acetone at 20℃;98%
1-(2-((2-hydroxybenzoyl)oxy)ethyl)-3-methylimidazolium chloride

1-(2-((2-hydroxybenzoyl)oxy)ethyl)-3-methylimidazolium chloride

sodium salicylate
54-21-7

sodium salicylate

1-(2-((2-hydroxybenzoyl)oxy)ethyl)-3-methylimidazolium tetrafluoroborate

1-(2-((2-hydroxybenzoyl)oxy)ethyl)-3-methylimidazolium tetrafluoroborate

Conditions
ConditionsYield
In acetonitrile at 20℃; for 24h;98%
sodium salicylate
54-21-7

sodium salicylate

benzyl chloride
100-44-7

benzyl chloride

benzyl salicylate
118-58-1

benzyl salicylate

Conditions
ConditionsYield
With potassium fluoride at 150℃; for 2h; Reagent/catalyst; Temperature;96.36%
With ethanol; copper
With diethylamine at 130 - 140℃;
toluene-3,4-dithiolatoantimony(III) chloride
57804-09-8

toluene-3,4-dithiolatoantimony(III) chloride

sodium salicylate
54-21-7

sodium salicylate

toluene-3,4-dithiolatoantimony(III) salicylate
1191898-48-2

toluene-3,4-dithiolatoantimony(III) salicylate

Conditions
ConditionsYield
In benzene byproducts: NaCl; reflux of toluene-3,4-dithiolatoantimony chloride and sodium salicylate in 1:1 molar ratio in benzene for 5 h; removal of solvent under reduced pressure, recrystn. in CH2Cl2; elem. anal.;96%
Imipramine hydrochloride
113-52-0

Imipramine hydrochloride

sodium salicylate
54-21-7

sodium salicylate

imipramine salicylate
1085510-17-3

imipramine salicylate

Conditions
ConditionsYield
In water at 20 - 62℃; for 19.95h;95.1%
In water at 20 - 62℃; for 19.95h;95.1%
didecyldimethylammonium chloride
7173-51-5

didecyldimethylammonium chloride

sodium salicylate
54-21-7

sodium salicylate

didecyldimethylammonium salicylate
934544-38-4

didecyldimethylammonium salicylate

Conditions
ConditionsYield
In water at 40℃; for 1h;95%
sodium salicylate
54-21-7

sodium salicylate

1-ethyl-3-methyl-1H-imidazol-3-ium chloride
65039-09-0

1-ethyl-3-methyl-1H-imidazol-3-ium chloride

1-ethyl-3-methylimidazolium 2-hydroxybenzoate
945611-28-9

1-ethyl-3-methylimidazolium 2-hydroxybenzoate

Conditions
ConditionsYield
In acetone at 20℃; for 24h; Inert atmosphere;95%
In acetonitrile at 20℃; for 24h; Inert atmosphere;94%
cerium(III) chloride heptahydrate

cerium(III) chloride heptahydrate

water
7732-18-5

water

sodium salicylate
54-21-7

sodium salicylate

cerium salicylate monohydrate

cerium salicylate monohydrate

Conditions
ConditionsYield
for 0.166667h; pH=5;95%
8-quinolinol
148-24-3

8-quinolinol

praseodymium(III) chloride hexahydrate

praseodymium(III) chloride hexahydrate

sodium salicylate
54-21-7

sodium salicylate

[Pr(salicylate)2(8-hydroxyquinoline(-1H))]
738614-57-8

[Pr(salicylate)2(8-hydroxyquinoline(-1H))]

Conditions
ConditionsYield
In neat (no solvent, solid phase) sodium salicylate, 8-hydroxyquinoline (3:1 molar ratio) mixed and groundin agate mortar for 30 min; PrCl3*6H2O added; mixt. was ground for 30 m in; washed (H2O, abs. EtOH); dried (vac.) for 6 hs; elem. anal.;94%
8-quinolinol
148-24-3

8-quinolinol

yttrium(III) chloride hexahydrate

yttrium(III) chloride hexahydrate

sodium salicylate
54-21-7

sodium salicylate

[Y(salicylate)2(8-hydroxyquinoline(-1H))]
171566-66-8

[Y(salicylate)2(8-hydroxyquinoline(-1H))]

Conditions
ConditionsYield
In neat (no solvent, solid phase) sodium salicylate, 8-hydroxyquinoline (3:1 molar ratio) mixed and groundin agate mortar for 30 min; YCl3*6H2O added; mixt. was ground for 30 mi n; washed (H2O, abs. EtOH); dried (vac.) for 6 hs; elem. anal.;93%
8-quinolinol
148-24-3

8-quinolinol

cerium(III) chloride hexahydrate

cerium(III) chloride hexahydrate

sodium salicylate
54-21-7

sodium salicylate

[Ce(salicylate)2(8-hydroxyquinoline(-1H))]
738614-56-7

[Ce(salicylate)2(8-hydroxyquinoline(-1H))]

Conditions
ConditionsYield
In neat (no solvent, solid phase) sodium salicylate, 8-hydroxyquinoline (3:1 molar ratio) mixed and groundin agate mortar for 30 min; CeCl3*6H2O added; mixt. was ground for 30 m in; washed (H2O, abs. EtOH); dried (vac.) for 6 hs; elem. anal.;93%
methylene chloride
74-87-3

methylene chloride

sodium salicylate
54-21-7

sodium salicylate

methyl salicylate
119-36-8

methyl salicylate

Conditions
ConditionsYield
With benzyltriethylammonium bromide In toluene at 80 - 90℃; under 3000.3 - 4500.45 Torr; for 1h;92.8%
8-quinolinol
148-24-3

8-quinolinol

lanthanum(III) chloride hexahydrate

lanthanum(III) chloride hexahydrate

sodium salicylate
54-21-7

sodium salicylate

[La(salicylate)2(8-hydroxyquinoline(-1H))]
171566-67-9, 847358-48-9, 932021-86-8

[La(salicylate)2(8-hydroxyquinoline(-1H))]

Conditions
ConditionsYield
In neat (no solvent, solid phase) sodium salicylate, 8-hydroxyquinoline (3:1 molar ratio) mixed and groundin agate mortar for 30 min; LaCl3*6H2O added; mixt. was ground for 30 m in; washed (H2O, abs. EtOH); dried (vac.) for 6 hs; elem. anal.;92%
sodium salicylate
54-21-7

sodium salicylate

1-hexyl-3-methylimidazol-1-ium chloride
171058-17-6

1-hexyl-3-methylimidazol-1-ium chloride

1-hexyl-3-methylimidazolium 2-hydroxybenzoate

1-hexyl-3-methylimidazolium 2-hydroxybenzoate

Conditions
ConditionsYield
In acetonitrile at 20℃; for 24h; Inert atmosphere;92%
In acetonitrile at 24.99℃;
bis(O,O′-diisopropyldithiophosphato-S,S′)antimony(III) chloride
85961-69-9

bis(O,O′-diisopropyldithiophosphato-S,S′)antimony(III) chloride

sodium salicylate
54-21-7

sodium salicylate

[(Pri-O)2PS2]2SbOOC(OH)C6H4

[(Pri-O)2PS2]2SbOOC(OH)C6H4

Conditions
ConditionsYield
In benzene for 6h; Reflux;92%
chloro-(5,10,15,20-tetraphenylporphyrinato)thallium(III)
63848-51-1

chloro-(5,10,15,20-tetraphenylporphyrinato)thallium(III)

sodium salicylate
54-21-7

sodium salicylate

Tl(C44H28N4)(C7H5O3)*H2O
220761-83-1

Tl(C44H28N4)(C7H5O3)*H2O

Conditions
ConditionsYield
In methanol; chloroform refluxing (12 h); CH2Cl2 addn., extracting (distilled water);91.5%
sodium salicylate
54-21-7

sodium salicylate

Aliquat 336
5137-55-3

Aliquat 336

tricaprylmethylammonium salicylate
82534-59-6

tricaprylmethylammonium salicylate

Conditions
ConditionsYield
In water; acetone at 20℃; for 24h; Inert atmosphere;91%
didecyldimethylammonium saccharinate
934544-24-8

didecyldimethylammonium saccharinate

sodium salicylate
54-21-7

sodium salicylate

didecyldimethylammonium salicylate
934544-38-4

didecyldimethylammonium salicylate

Conditions
ConditionsYield
In water at 60℃; for 2h;90%
sodium salicylate
54-21-7

sodium salicylate

tricaprylmethylammonium salicylate
82534-59-6

tricaprylmethylammonium salicylate

Conditions
ConditionsYield
With Aliquat336 In chloroform for 4h;90%
monochloroantimony(III) bis(diisobutyldithiophosphate)
85988-65-4

monochloroantimony(III) bis(diisobutyldithiophosphate)

sodium salicylate
54-21-7

sodium salicylate

bis(diisobutyldithiophosphato)antimony(III) salicylate

bis(diisobutyldithiophosphato)antimony(III) salicylate

Conditions
ConditionsYield
In acetonitrile for 6h; Reflux;90%
8-dioxane-3-cobalt-bis(1,2-dicarbollide)
188478-29-7

8-dioxane-3-cobalt-bis(1,2-dicarbollide)

sodium salicylate
54-21-7

sodium salicylate

Na[1''-(3,3'-Co(8-O(CH2CH2O)2C(O)-1,2-C2B9H10)(1',2'-C2B9H11)-2''-OH-C6H4)]

Na[1''-(3,3'-Co(8-O(CH2CH2O)2C(O)-1,2-C2B9H10)(1',2'-C2B9H11)-2''-OH-C6H4)]

Conditions
ConditionsYield
In 1,2-dimethoxyethane under inert atm. soln. cobaltacarborane and sodium salicylate in DME wasstirred overnight; solvent was removed; elem. anal.;89.3%
sodium salicylate
54-21-7

sodium salicylate

tramadol hydrochloride
36282-47-0

tramadol hydrochloride

tramadolium salicylate

tramadolium salicylate

Conditions
ConditionsYield
In water; acetone at 20℃;89%

54-21-7Relevant articles and documents

Rate constants for reaction of hydroxyl radicals with sulfapyridine and aminosalicylic acids

Motohashi, Noriko,Saito, Yutaka

, p. 163 - 166 (1996)

Sulfasalazine, an anti-inflammatory drug, is metabolized to sulfapyridine and 5-aminosalicylic acid (5-ASA) which is therapeutically active. In the inflammation, active oxygen species have been suggested to play an important role. Among various active oxygen species, hydroxyl radical is known to be the most active radical. To elucidate the reactivity of sulfapyridine, 5- ASA, 4-ASA and 3-ASA with hydroxyl radicals, the rate constants were determined measuring the fluorescence of hydroxybenzoates induced by radiolysis hydroxylation of benzoate. The constant for 5-ASA, strongly fluorescent but insoluble in ether, was measured after ether extraction of hydroxybenzoates under acidic condition. For the other compounds, the rate constants were determined using a method which separates hydroxybenzoates by HPLC after the ether extraction, since the three compounds moved to the ether layer and interfered with the fluorescence of the hydroxybenzoates induced. Four rate constants were obtained in the range of 6.4-7.0 x 109 M-1 s- 1, showing that they similarly scavenge hydroxyl radicals in vitro.

Synthetic method of methyl salicylate

-

Paragraph 0016-0017; 0020-0021; 0024-0025, (2021/02/10)

The invention discloses a synthesis method of methyl salicylate. The method comprises the following steps: preparing sodium phenolate by using caustic soda flakes and phenol as raw materials, carryingout carboxylation reaction on the obtained sodium phenolate and carbon dioxide gas to obtain sodium salicylate, reacting the obtained sodium salicylate with chloromethane gas under the action of a phase transfer catalyst to obtain a crude methyl salicylate product containing a toluene solvent, neutralizing and washing the crude methyl salicylate product, recovering the toluene solvent at normal pressure, and carrying out vacuum distillation to obtain a finished methyl salicylate product. According to the method, a strong acid catalyst is not used, so that the wastewater amount is greatly reduced, and the corrosion to equipment and the pollution to the environment are reduced. According to the method, equipment is not seriously corroded, the wastewater amount is small, and the process is more environmentally friendly.

Evidence of co-operativity in the pre-micellar region in the hydrolytic cleavage of phenyl salicylate in the presence of cationic surfactants of CTAB, TTAB and CPC

Sen, Pratik K.,Chatterjee, Piyali,Pal, Biswajit

, p. 23 - 30 (2015/02/18)

The effects of cationic surfactants of cetyl trimethyl ammonium bromide (CTAB), tetradecyl trimethyl ammonium bromide (TTAB) and cetyl pyridinium chloride (CPC) on the kinetics of intramolecular general base catalyzed hydrolysis ([OH-] range 0.05-0.1 mol L-1) of phenyl salicylate have been studied at different temperatures. The rate is independent of [OH-] in the studied range. The anionic surfactant sodium dodecyl sulphate (SDS) has no effect on the rate. The presence of small amount of any of these cationic surfactants well below its critical micelle concentration markedly inhibits the rate of reaction suggesting a pre-micellar aggregation between the substrate and surfactant monomers. The kinetic data have been analyzed in terms of earlier reported models (Piszkiewicz's co-operativity model and Raghavan and Srinivasan's model) for micellar catalysis. The binding constants between the substrate and the surfactants evaluated from the two models are in good agreement. Three dimensional structure of the pre-micellar aggregate controls the approach of the nucleophile water molecule to the reaction center. The planar structure of the pyridinium head group of CPC provides less steric hindrance to the attacking water molecule that leads to the least enthalpy of activation for CPC among the three surfactants. The association between the negatively charged substrate and the cationic surfactant is favored owing to electrostatic as well as hydrophobic interactions. The binding between the substrate and pre-micelles follows the order: CPC > TTAB > CTAB.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1

What can I do for you?
Get Best Price

Get Best Price for 54-21-7